Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ Drugs
This "Pancreatic Cancer- Competitive landscape, 2023" report provides comprehensive insights about 250+ companies and 300+ drugs in Pancreatic Cancer Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In March 2023, Adaptimmune Therapeutics plc. and TCR Therapeutics Inc. (NASDAQ: TCRR), announced entry into a definitive agreement under which Adaptimmune will combine with TCR in an all-stock transaction to create a preeminent cell therapy company focused on treating solid tumors.
The combination provides extensive benefits for clinical development and product delivery supported by complementary technology platforms. As a result, and following the closing of the transaction, it is anticipated that the combined company's cash runway will extend into 2026.
In February 2023, Akamis Bio, announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy (PICI) to include a clinical collaboration with the Cancer Research Institute (CRI) that will focus on advancing novel treatments for pancreatic cancer.
As part of the Akamis Bio, PICI, and CRI partnership, NG-350A, an immuno-stimulatory tumor gene therapy driving intratumoral expression of a CD40 agonist monoclonal antibody, will be evaluated in combination with standard-of-care chemotherapy and the CTLA-4 inhibitor ipilimumab (YERVOY).
In February 2023, Gritstone bio, Inc. announced that it has entered into a clinical trial agreement with the National Cancer Institute (NCI), an institute of the National Institutes of Health, to evaluate an autologous T cell therapy expressing a T cell receptor targeting mutated KRAS in combination with Gritstone's KRAS-directed vaccine candidate, SLATE-KRAS, in a Phase 1 study. Under the terms of the agreement, NCI will identify patients with metastatic cancer that are eligible for adoptive cell transfer based on the presence of a G12V or G12D KRAS mutation (KRASmut).
In February 2023, Keymed Biosciences Inc., jointly announced a global exclusive license agreement with AstraZeneca for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC). Under the license agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialization of CMG901 globally. CMG901 is currently in a Phase I clinical trial for the treatment of Claudin 18.2-positive solid tumors.
In January 2023, AIM ImmunoTech Inc. announced it has entered into an external sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca. Under the agreement, Erasmus MC is planning to perform an investigator-initiated clinical study, entitled "Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy effect. DURIPANC Study," in which it will use both Study Drugs provided by AstraZeneca and AIM ImmunoTech.
Pancreatic Cancer Analytical Perspective
In-depth Commercial Assessment: Pancreatic Cancer Collaboration Analysis by Companies
The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pancreatic Cancer drugs?
- How many Pancreatic Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pancreatic Cancer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pancreatic Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pancreatic Cancer and their status?
- What are the key designations that have been granted to the emerging and approved drugs?
Key Players
- Panbela Therapeutics
- ERYtech Pharma
- Jiangsu HengRui Medicine Co., Ltd.
- FibroGen
- Novartis AG
- AB Science
- TME Pharma AG
- Intensity Therapeutics
- Silenseed LTD
- SynerGene Therapeutics
- Elevation oncology
- Salspera LLC
- Redx Pharma Plc
- AIM ImmunoTech Inc.
- Rain Oncology
- Jazz Pharmaceuticals
- Invyte Corporation
- Immodulon Therapeutics Ltd
- GSK plc
- Merck Sharp & Dohme LLC
- Roche
- Helsinn Healthcare SA
- Argenus Inc.
- Actuate Therapeutics
- OSE Immunotherapeutics
- Incyte Corporation
- Galera Therapeutics
- CSPC ZhongQi Pharmaceutical Technology
- Astellas Pharma Global Development, Inc.
- NanOlogy
- Theriva Biologics
- AstraZeneca
- Berg, LLC
- Agenus
- ABVC BioPharma, Inc.
- Boehringer Ingelheim
- Alligator Bioscience
- CARsgenTherapeutics Co.,Ltd
- Purple Biotech Ltd.
- Lisata Therapeutics
- Chongqing Precision Biotech Co., Ltd
- Cybrexa Therapeutics
- Bold Therapeutics
- BioNTech SE
- Bristol-Myers Squibb
- DEKA Biosciences
- Senhwa Biosciences
- Cue Biopharma
- Carisma Therapeutics Inc
Key Products
- Olaptesed pegol
- INT230-6
- SBP-101
- Masitinib
NIS793 - siG12D LODER
- SGT-53
- Seribantumab
- Salmonella-IL2
- RXC004
- Rintatolimod
- RAIN-32
- Lurbinectedin
- Retifanlimab
- IMM-101
- GSK2256098
- Belzutifan
- Atezolizumab
- Anamorelin
- AGEN1423
- Elraglusib
- OSE2101
- Epacadostat
- GC4711
- Docetaxel
- Zolbetuximab
- NanoPac
- VCN-01
- Danvatirsen
- BPM31510
- Botensilimab
- ABV-1703
- BI 907828
- Mitazalimab
- CT041
- CM24
- CEND-1
- CEA-targeted CAR-T cells
- CBX-12
- BOLD-100
- BNT141
- BMS-813160
- DK210
- CX-5461
- CUE-102
- CT-0508
For more information about this report visit https://www.researchandmarkets.com/r/nub2rq
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For
For GMT Office Hours Call +353-1-416-8900
Fax (outside
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/global-pancreatic-cancer-competitive-landscape-report-2023-comprehensive-insights-about-250-companies-and-300-drugs-301818292.html
SOURCE Research and Markets
